Milatuzumab – a promising new immunotherapeutic agent

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Leonard JP, Friedberg JW, Hagemeister FB, Levine AM. Combination treatment approaches and novel therapies for lymphoma. Clin Adv Hematol Oncol 2007; 5:(Suppl 12):4-20
   PubMedGoogle Scholar
• Shackelford DA, Strominger JL. Demonstration of structural polymorphism among HLA-DR light chains by two-dimensional gel electrophoresis. J Exp Med 1980;151:144-65
   PubMed Web of Science ®Google Scholar
• Jones PP, Murphy DB, Hewgill D, McDevitt HO. Detection of a common polypeptide chain in I–A and I–E sub-region immunoprecipitates. Mol Immunol 1979;16:51-60
   PubMed Web of Science ®Google Scholar
• Long EO, Strubin M, Wake CT, Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens. Proc Natl Acad Sci USA 1983;80:5714-18
   PubMed Web of Science ®Google Scholar
• Dixon AM, Stanley BJ, Matthews EE, Invariant chain transmembrane domain trimerization: a step in MHC class II assembly. Biochemistry 2006;45:5228-34
   PubMed Web of Science ®Google Scholar
• Lamb CA, Cresswell PL. Assembly and transport properties of invariant chain trimers and HLA-DR-invariant chain complexes. J Immunol 1992;148:3478-82
   PubMed Web of Science ®Google Scholar
• Loss GE Jr, Sant AJ. Invariant chain retains MHC class II molecules in the endocytic pathway. J Immunol 1993;150:3187-97
   PubMed Web of Science ®Google Scholar
• Lotteau V, Teyton L, Peleraux A, Intracellular transport of class II MHC molecules directed by invariant chain. Nature 1990;348:600-5
   PubMed Web of Science ®Google Scholar
• Swier K, Miller J. Efficient internalization of MHC class II-invariant chain complexes is not sufficient for invariant chain proteolysis and class II antigen presentation. J Immunol 1995;155:630-43
   PubMed Web of Science ®Google Scholar
• Manoury B, Mazzeo D, Li DN, Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone. Immunity 2003;18:489-98
   PubMed Web of Science ®Google Scholar
• Morton PA, Zacheis ML, Giacoletto KS, Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J Immunol 1995;154:137-50
   PubMed Web of Science ®Google Scholar
• Riese RJ, Wolf PR, Bromme D, Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996;4:357-66
   PubMed Web of Science ®Google Scholar
• Bania J, Gatti E, Lelouard H, Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc Natl Acad Sci USA 2003;100:6664-9
   PubMed Web of Science ®Google Scholar
• Cresswell P. Invariant chain structure and MHC class II function. Cell 1996;84:505-7
   PubMed Web of Science ®Google Scholar
• Newcomb JR, Cresswell P. Structural analysis of proteolytic products of MHC class II-invariant chain complexes generated in vivo. J Immunol 1993;151:4153-63
   PubMed Web of Science ®Google Scholar
• Zachgo S, Dobberstein B, Griffiths G. A block in degradation of MHC class II-associated invariant chain correlates with a reduction in transport from endosome carrier vesicles to the prelysosome compartment. J Cell Sci 1992;103:811-22
   PubMed Web of Science ®Google Scholar
• Neefjes JJ, Ploegh HL. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance alpha beta heterodimers in endosomes. EMBO J 1992;11:411-16
   PubMed Web of Science ®Google Scholar
• Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997;16:2851-60
   PubMed Web of Science ®Google Scholar
• Genuardi M, Saunders GF. Localization of the HLA class II-associated invariant chain gene to human chromosome band 5q32. Immunogenetics 1988;28:53-6
   PubMed Web of Science ®Google Scholar
• Tai AK, Zhou G, Chau K, Ono SJ. Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription. Mol Immunol 1999;36:447-60
   PubMed Web of Science ®Google Scholar
• Wright KL, Moore TL, Vilen BJ, Major histocompatibility complex class II-associated invariant chain gene expression is up-regulated by cooperative interactions of Sp1 and NF-Y. J Biol Chem 1995;270:20978-86
   PubMed Web of Science ®Google Scholar
• Zhu L, Jones PP. Transcriptional control of the invariant chain gene involves promoter and enhancer elements common to and distinct from major histocompatibility complex class II genes. Mol Cell Biol 1990;10:3906-16
   PubMed Web of Science ®Google Scholar
• Dellabona P, Latron F, Maffei A, Transcriptional control of MHC class II gene expression during differentiation from B cells to plasma cells. J Immunol 1989;142:2902-10
   PubMed Web of Science ®Google Scholar
• Halper J, Fu SM, Wang CY, Patterns of expression of human ‘Ia-like’ antigens during the terminal stages of B cell development. J Immunol 1978;120:1480-4
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Rogers PR, Grusby MJ, B lymphocyte development and activation independent of MHC class II expression. J Immunol 1993;150:1223-33
   PubMed Web of Science ®Google Scholar
• Cosgrove D, Gray D, Dierich A, Mice lacking MHC class II molecules. Cell 1991;66:1051-66
   PubMedGoogle Scholar
• Shachar I, Flavell RA. Requirement for invariant chain in B cell maturation and function. Science 1996;274:106-8
   PubMed Web of Science ®Google Scholar
• Matza D, Kerem A, Medvedovsky H, Invariant chain-induced B cell differentiation requires intramembrane proteolytic release of the cytosolic domain. Immunity 2002;17:549-60
   PubMed Web of Science ®Google Scholar
• Becker-Herman S, Arie G, Medvedovsky H, CD74 is a member of the regulated intramembrane proteolysis-processed protein family. Mol Biol Cell 2005;16:5061-9
   PubMed Web of Science ®Google Scholar
• Matza D, Lantner F, Bogoch Y, Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity. Proc Natl Acad Sci USA 2002;9:3018-23
   Google Scholar
• Lantner F, Starlets D, Gore Y, CD74 induces TAp63 expression leading to B-cell survival. Blood 2007;110:4303-11
   PubMed Web of Science ®Google Scholar
• Leng L, Metz CN, Fang Y, MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76
   PubMed Web of Science ®Google Scholar
• Gore Y, Starlets D, Maharshak N, Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008;283:2784-92
   PubMed Web of Science ®Google Scholar
• Shi X, Leng L, Wang T, CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006;25:595-606
   PubMed Web of Science ®Google Scholar
• Lue H, Thiele M, Franz J, Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 2007;26:5046-59
   PubMed Web of Science ®Google Scholar
• Schwartz V, Lue H, Kraemer S, A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett 2009;583:2749-57
   PubMed Web of Science ®Google Scholar
• Bernhagen J, Krohn R, Lue H, MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007;13:587-96
   PubMed Web of Science ®Google Scholar
• Stein R, Mattes MJ, Cardillo TM, CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556-63s
   PubMed Web of Science ®Google Scholar
• Burton JD, Ely S, Reddy PK, CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10:6606-11
   PubMed Web of Science ®Google Scholar
• Su AI, Wiltshire T, Batalov S, A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004;101:6062-7
   PubMed Web of Science ®Google Scholar
• Starlets D, Gore Y, Binsky I, Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006;107:4807-16
   PubMed Web of Science ®Google Scholar
• Ioachim HL, Pambuccian SE, Hekimgil M, Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am J Surg Pathol 1996;20:64-71
   PubMed Web of Science ®Google Scholar
• Binsky I, Haran M, Starlets D, IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B-cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007;104:13408-13
   PubMed Web of Science ®Google Scholar
• Barrera CA, Beswick EJ, Sierra JC, Polarized expression of CD74 by gastric epithelial cells. J Histochem Cytochem 2005;53:1481-9
   PubMed Web of Science ®Google Scholar
• Beswick EJ, Pinchuk IV, Suarez G, Helicobacter pylori CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. J Immunol 2006;176:6794-801
   PubMed Web of Science ®Google Scholar
• Tamori Y, Tan X, Nakagawa K, Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma. Oncol Rep 2005;14:873-7
   PubMed Web of Science ®Google Scholar
• Meyer-Siegler KL, Iczkowski KA, Vera PL. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. BMC Cancer 2005;5:73
   PubMedGoogle Scholar
• Meyer-Siegler KL, Iczkowski KA, Leng L, Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006;177:8730-9
   PubMed Web of Science ®Google Scholar
• Datta MW, Shahsafaei A, Nadler LM, Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol 2000;8:210-15
   PubMedGoogle Scholar
• Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer 1997;79:2115-24
   PubMed Web of Science ®Google Scholar
• Cuthbert RJ, Wilson JM, Scott N, Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer 2009;45:1654-63
   PubMed Web of Science ®Google Scholar
• Koide N, Yamada T, Shibata R, Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin Cancer Res 2006;12:2419-26
   PubMed Web of Science ®Google Scholar
• Verjans E, Noetzel E, Bektas N, Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 2009;9:230
   PubMed Web of Science ®Google Scholar
• Qiu G, Goodchild J, Humphreys RE, Xu M. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells. Cancer Immunol Immunother 1999;8:499-506
   Google Scholar
• Xu M, Lu X, Kallinteris NL, Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Curr Opin Mol Ther 2004;6:160-5
   PubMed Web of Science ®Google Scholar
• Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 1999;98:296-302
   PubMed Web of Science ®Google Scholar
• Kwapien RP, Giles RC, Geil RG, Casey HW. Basaloid adenomas of the mammary gland in beagle dogs administered investigational contraceptive steroids. J Natl Cancer Inst 1977;59:933-9
   PubMed Web of Science ®Google Scholar
• Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, Goldenberg DM. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 1989;49:4568-77
   PubMed Web of Science ®Google Scholar
• Hansen HJ, Ong GL, Diril H, Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320:293-300
   PubMed Web of Science ®Google Scholar
• Govindan SV, Goldenberg DM, Elsamra SE, Radionuclides linked to a CD74 antibody (LL1) as therapeutic agents for B-cell lymphoma: comparison of Auger electron emitters with beta-particle emitters. J Nucl Med 2000;41:2089-97
   PubMed Web of Science ®Google Scholar
• Ochakovskaya R, Osorio L, Goldenberg DM, Mattes MJ. Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium. Clin Cancer Res 2001;7:1505-10
   PubMed Web of Science ®Google Scholar
• Griffiths GL, Mattes MJ, Stein R, Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9:6567-71
   PubMed Web of Science ®Google Scholar
• Sapra P, Stein R, Pickett J, Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005;11:5257-64
   PubMed Web of Science ®Google Scholar
• Chang CH, Sapra P, Vanama SS, Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106:4308-14
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Cardillo TM, Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104:3705-11
   PubMed Web of Science ®Google Scholar
• Berkova Z, Wang S, Wise J, CD74 is a regulator of Fas-mediated apoptotic signaling. Blood 2008;112:976-6
   Web of Science ®Google Scholar
• Stein R, Smith MR, Chen S, Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res 2009;15:2808-17
   PubMed Web of Science ®Google Scholar
• Kaufman JNR, Stadtmauer E, Chanan-Khan A, First trial of humanized anti-CD-74 monoclonal antibody (Mab), milatuzumab in multiple myeloma. Blood 2008;112:1266-7
   Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73
   PubMed Web of Science ®Google Scholar
• Nagata S, Jin YF, Yoshizato K, CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol 2009;16:2531-8
   PubMed Web of Science ®Google Scholar
• Kitange G, Carlson B, Schroede RM, CD74 is overexpressed in cells from temozolamide resistant glioblastoma xenografts and the expression in patient samples is associated with poor overall survival [A3209]. American Association of Cancer Research Annual Meeting 12 – 16 April 2008, San Diego, USA
   Google Scholar
• Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol 2009;15:2855-61
   PubMed Web of Science ®Google Scholar
• Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia 1999;13:1854-8
   PubMed Web of Science ®Google Scholar
• Muller M, Scaffidi CA, Galle PR, The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur Cytokine Netw 1998;9:685-6
   PubMed Web of Science ®Google Scholar
• Gold D, Burton J, Desani J, Expression of CD74 in gastrointestinal cancers as a target for immunotherapy. J Clin Oncol 2009 [A168] ASCO 2009 Gastrointestinal Cancer Symposium, 15 – 17 January 2009, San Francisco, USA
   Google Scholar
• de Totero D, Montera M, Rosso O, Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. Hematol J 2004;5:152-60
   PubMedGoogle Scholar
• Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:498-501
   PubMed Web of Science ®Google Scholar
• Takahashi K, Koga K, Linge HM, Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Respir Res 2009;10:33
   PubMed Web of Science ®Google Scholar
• Miller EJ, Li J, Leng L, Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature 2008;451:578-82
   PubMed Web of Science ®Google Scholar